Interventional Highlights From the New ACC/AHA Valve Disease Guidelines
Mirvat Alasnag, MB, BCh, Director of Catheterization Laboratory Military Hospital, Jeddah-Saudi Arabia, member of the American College of Cardiology (ACC) Interventional Leadership Council, and David Cohen, MD, Director of Clinical and Outcomes Research at Cardiovascular Research Foundation and Director of Academic Affairs at Saint Francis Hospital, discuss highlights from the latest ACC and American Heart Association valve disease guidelines, with emphasis on the role of the heart team, life expectancy and age as determinants for transcatheter aortic valve replacement (TAVR), role of the endotracheal tube in asymptomatic patients, antithrombotic regimens for TAVR, and indications for mitral valve transcatheter interventions.
Video 1: Interventional Highlights From the New ACC/AHA Valve Disease Guidelines
- Writing Committee Members, Otto CM, Nishimura RA, et al. 2020 ACC/AHA Guideline for the Management of Patients With Valvular Heart Disease: Executive Summary: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. J Am Coll Cardiol 2021;77:450-500.
Keywords: Transcatheter Aortic Valve Replacement, Fibrinolytic Agents, Mitral Valve, Tricuspid Valve Insufficiency, American Heart Association, Hospitals, Military, Laboratories, Leadership, Life Expectancy, Aortic Valve Stenosis, Echocardiography, Cardiomyopathy, Hypertrophic, Catheterization, Outcome Assessment, Health Care, Clinical Medicine, Intubation, Intratracheal, Heart Valve Diseases, Coronary Angiography
< Back to Listings